Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the TargetSITOHY, Basel; NAGY, Janice A; DVORAK, Harold F et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 8, pp 1909-1914, issn 0008-5472, 6 p.Article

Synthesis, in silico, in vitro, and in vivo investigation of 5-[¹¹C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2CABALLERO, Julio; MUNOZ, Camila; ALZATE-MORALES, Jans H et al.European journal of medicinal chemistry. 2012, Vol 58, pp 272-280, issn 0223-5234, 9 p.Article

Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitorDONGCHUN WANG; FENG TANG; SEN WANG et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 1, pp 173-183, issn 0344-5704, 11 p.Article

Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptideLOCAL, Pedro M; MOREA, Veronica; TRAMONTANO, Anna et al.European journal of cancer (1990). 2008, Vol 44, Num 13, pp 1914-1921, issn 0959-8049, 8 p.Article

The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumorsJIANJUN LU; JACKSON, John K; GLEAVE, Martin E et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 6, pp 997-1005, issn 0344-5704, 9 p.Article

Ramucirumab: First Global ApprovalPOOLE, Raewyn M; VAIDYA, Asha.Drugs (Basel). 2014, Vol 74, Num 9, pp 1047-1058, issn 0012-6667, 12 p.Article

Lymphangiogenesis in Lymphangioleiomyomatosis: Its implication in the progression of LymphangioleiomyomatosisKUMASAKA, Toshio; SEYAMA, Kuniaki; SUDA, Koichi et al.The American journal of surgical pathology. 2004, Vol 28, Num 8, pp 1007-1016, issn 0147-5185, 10 p.Article

Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis modelBRAVE, Sandra R; EBERLEIN, Cath; SHIBUYA, Masabumi et al.Angiogenesis (London). 2010, Vol 13, Num 4, pp 337-347, issn 0969-6970, 11 p.Article

Elevated Vascular Endothelial Growth Factor Receptor-2 Abundance Contributes to Increased Angiogenesis in Vascular Endothelial Growth Factor Receptor-1―Deficient MiceHO, Vivienne C; DUAN, Li-Juan; CRONIN, Chunxia et al.Circulation (New York, N.Y.). 2012, Vol 126, Num 6, pp 741-752, issn 0009-7322, 12 p.Article

Rational Combination of Targeted Therapies As A Strategy to Overcome The Mechanisms of Resistance to Inhibitors of EGFR Signaling : Anti-cancer-drugsBIANCO, Roberto; DAMIANO, Vincenzo; GELARDI, Teresa et al.Current pharmaceutical design. 2007, Vol 13, Num 33, pp 3358-3367, issn 1381-6128, 10 p.Article

Vascular Endothelial Growth Factors and Their Receptors and Regulators in Gestational Trophoblastic Diseases and Normal PlacentaSINGH, Margit; KINDELBERGER, David; NAGYMANYOKI, Zoltan et al.Journal of reproductive medicine. 2012, Vol 57, Num 5-6, pp 197-203, issn 0024-7758, 7 p.Conference Paper

Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvantXU, Gui-Lian; ZHANG, Ke-Qin; BO GUO et al.Vaccine. 2010, Vol 28, Num 44, pp 7221-7227, issn 0264-410X, 7 p.Article

Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinasesNAKAMURA, Hiroyuki; SASAKI, Yusuke; UNO, Masaharu et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 19, pp 5127-5131, issn 0960-894X, 5 p.Article

The Effect of Combination Anti-Endothelial Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Targeted Therapy on Lymph Node Metastasis : A Study in an Orthotopic Nude Mouse Model of Squamous Cell Carcinoma of the Oral TongueSANO, Daisuke; CHOI, Sungweon; LUKA MILAS, Zvonimir et al.Archives of otolaryngology, head & neck surgery. 2009, Vol 135, Num 4, pp 411-420, issn 0886-4470, 10 p.Article

Tumor-induced lymphangiogenesis : A target for cancer therapy?THIELE, Wilko; SLEEMAN, Jonathan P.Journal of biotechnology. 2006, Vol 124, Num 1, pp 224-241, issn 0168-1656, 18 p.Article

Tyrosine Kinase Inhibitors : A Potential Approach to the Treatment of Hepatocellular Carcinoma : Resent and future therapies for the hepatocellular carcinomaGIANNELLI, G; NAPOLI, N; ANTONACI, S et al.Current pharmaceutical design. 2007, Vol 13, Num 32, pp 3301-3304, issn 1381-6128, 4 p.Article

Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma developmentYOSHIJI, Hitoshi; KURIYAMA, Shigeki; MASAKI, Tsutomu et al.Journal of hepatology. 2004, Vol 41, Num 1, pp 97-103, issn 0168-8278, 7 p.Article

Valeur pronostique de l'expression des recepteurs du VEGF, VEGFR-1 (FLT-1) et VEGFR-2 (KDR/FLK-1) dans le cancer du sein = Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinomaDALES, Jean-Philippe; GARCIA, Stéphane; CHARPIN, Colette et al.Annales de pathologie (Paris). 2003, Vol 23, Num 4, pp 297-305, issn 0242-6498, 9 p.Article

Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinomaMEUNIER-CARPENTIER, Séverine; DALES, Jean-Philippe; DJEMLI, Amina et al.International journal of oncology. 2005, Vol 26, Num 4, pp 977-984, issn 1019-6439, 8 p.Article

Substitution of C-terminus of VEGFR-2 with VEGFR-1 promotes VEGFR-1 activation and endothelial cell proliferationMEYER, Rosana D; SINGH, Amrik; MAJNOUN, Fredric et al.Oncogene (Basingstoke). 2004, Vol 23, Num 32, pp 5523-5531, issn 0950-9232, 9 p.Article

Angiorésistance: mécanismes et physiopathoiogie = Angioresistance: mechanisms and pathophysiologyZAANAN, Aziz.La Lettre du cancérologue (Boulogne). 2013, Vol 22, Num 6, pp 227-229, issn 1165-113X, 3 p.Conference Paper

Sunitinib in pancreatic neuroendocrine tumors : NEUROENDOCRINE TUMORSRAYMOND, Eric; HAMMEL, Pascal; DREYER, Chantal et al.Targeted oncology. 2012, Vol 7, Num 2, pp 117-125, issn 1776-2596, 9 p.Article

Radiolabeled Small Molecule Inhibitors of VEGFR - Recent AdvancesKNIESS, Torsten.Current pharmaceutical design (Print). 2012, Vol 18, Num 20, pp 2867-2874, issn 1381-6128, 8 p.Article

Place des traitements antiangiogéniques dans le traitement des tumeurs endocrines peu différenciées = Targeted anti-angiogenics therapies for poorly differenciated neuroendocrine tumoursDAHAN, Laetitia; SEITZ, Jean-François.Hépato-gastro (Montrouge). 2011, Vol 18, issn 1253-7020, S31-S33, SUP2Article

Grandes classes thérapeutiques et différents modes d'action : Antiangiogéniques (1re partie) = Classes of agents and mechanisms of actionLETOURNEAU, C.La Lettre du cancérologue (Boulogne). 2010, Vol 19, Num 9, pp 508-511, issn 1165-113X, 4 p.Article